319 related articles for article (PubMed ID: 29728717)
1. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial.
Welsh P; Rankin N; Li Q; Mark PB; Würtz P; Ala-Korpela M; Marre M; Poulter N; Hamet P; Chalmers J; Woodward M; Sattar N
Diabetologia; 2018 Jul; 61(7):1581-1591. PubMed ID: 29728717
[TBL] [Abstract][Full Text] [Related]
2. Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study.
Harris K; Oshima M; Sattar N; Würtz P; Jun M; Welsh P; Hamet P; Harrap S; Poulter N; Chalmers J; Woodward M
Diabetologia; 2020 Aug; 63(8):1637-1647. PubMed ID: 32385604
[TBL] [Abstract][Full Text] [Related]
3. Importance of hematological parameters for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study.
Cardoso CRL; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Jul; 20(1):133. PubMed ID: 34229668
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
5. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study.
Garofolo M; Gualdani E; Giannarelli R; Aragona M; Campi F; Lucchesi D; Daniele G; Miccoli R; Francesconi P; Del Prato S; Penno G
Cardiovasc Diabetol; 2019 Nov; 18(1):159. PubMed ID: 31733651
[TBL] [Abstract][Full Text] [Related]
6. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CRL; Leite NC; Moram CBM; Salles GF
Cardiovasc Diabetol; 2018 Feb; 17(1):33. PubMed ID: 29477146
[TBL] [Abstract][Full Text] [Related]
7. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes.
Carlsson AC; Östgren CJ; Nystrom FH; Länne T; Jennersjö P; Larsson A; Ärnlöv J
Cardiovasc Diabetol; 2016 Feb; 15():40. PubMed ID: 26928194
[TBL] [Abstract][Full Text] [Related]
8. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
[TBL] [Abstract][Full Text] [Related]
9. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
[TBL] [Abstract][Full Text] [Related]
10. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial.
Welsh P; Woodward M; Hillis GS; Li Q; Marre M; Williams B; Poulter N; Ryan L; Harrap S; Patel A; Chalmers J; Sattar N
Diabetes Care; 2014 Aug; 37(8):2202-10. PubMed ID: 24879844
[TBL] [Abstract][Full Text] [Related]
11. BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study.
Polemiti E; Baudry J; Kuxhaus O; Jäger S; Bergmann MM; Weikert C; Schulze MB
Diabetologia; 2021 Apr; 64(4):814-825. PubMed ID: 33452586
[TBL] [Abstract][Full Text] [Related]
12. Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.
Kim H; Wang D; Chalmers J; Jun M; Zoungas S; Marre M; Hamet P; Harrap S; Mancia G; Poulter NR; Cooper ME; Woodward M; Selvin E; Rebholz CM
J Diabetes; 2020 Dec; 12(12):929-941. PubMed ID: 32609422
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the association of prediabetes and type 2 diabetes with microvascular complications and function: The Maastricht Study.
de Ritter R; Sep SJS; van der Kallen CJH; van Greevenbroek MMJ; de Jong M; Vos RC; Bots ML; Reulen JPH; Houben AJHM; Webers CAB; Berendschot TTJM; Dagnelie PC; Eussen SJPM; Schram MT; Koster A; Peters SAE; Stehouwer CDA
Cardiovasc Diabetol; 2021 May; 20(1):102. PubMed ID: 33962619
[TBL] [Abstract][Full Text] [Related]
14. Fetuin-A and risk of diabetes-related vascular complications: a prospective study.
Birukov A; Polemiti E; Jäger S; Stefan N; Schulze MB
Cardiovasc Diabetol; 2022 Jan; 21(1):6. PubMed ID: 34998417
[TBL] [Abstract][Full Text] [Related]
15. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CRL; Leite NC; Salles GF
Cardiovasc Diabetol; 2020 May; 19(1):50. PubMed ID: 32359350
[TBL] [Abstract][Full Text] [Related]
16. Eye complications and markers of morbidity and mortality in long-term type 1 diabetes.
Grauslund J
Acta Ophthalmol; 2011 Feb; 89 Thesis 1():1-19. PubMed ID: 21443578
[TBL] [Abstract][Full Text] [Related]
17. Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.
Yang CY; Su PF; Hung JY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jul; 19(1):105. PubMed ID: 32631323
[TBL] [Abstract][Full Text] [Related]
18. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study.
Lowe G; Woodward M; Hillis G; Rumley A; Li Q; Harrap S; Marre M; Hamet P; Patel A; Poulter N; Chalmers J
Diabetes; 2014 Mar; 63(3):1115-23. PubMed ID: 24222348
[TBL] [Abstract][Full Text] [Related]
19. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes.
Zoungas S; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; Marre M; Patel A; Poulter N; Williams B; Chalmers J;
Diabetologia; 2014 Dec; 57(12):2465-74. PubMed ID: 25226881
[TBL] [Abstract][Full Text] [Related]
20. Preserved Ratio Impaired Spirometry and Risks of Macrovascular, Microvascular Complications and Mortality Among Individuals With Type 2 Diabetes.
Li G; Jankowich MD; Wu L; Lu Y; Shao L; Lu X; Fan Y; Pan CW; Wu Y; Ke C
Chest; 2023 Nov; 164(5):1268-1280. PubMed ID: 37356807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
